10 Stocks Under $10 that Will Triple

7. Arvinas, Inc. (NASDAQ:ARVN)

Upside Potential: 331.32%

Number Of Hedge Funds: 32

Arvinas, Inc. (NASDAQ:ARVN) develops treatments that break down disease-causing proteins using its PROTAC (Proteolysis Targeting Chimera) technology. The company’s main drugs target prostate cancer (Bavdegalutamide and ARV-766) and breast cancer (ARV-471), all in Phase 3 trials. Arvinas is also working on ARV-393 for B-cell malignancies, ARV-102 for brain diseases, and a KRAS G12D degrader still in lab testing.

Arvinas, Inc. (NASDAQ:ARVN)’s revenue jumped 235% to $263.4 million in 2024, up from $78.5 million in 2023. This surge came from Novartis agreements with revenue of $162.4 million and Pfizer collaborations with a boost of $21.7 million. However, cash reserves fell to $1,039.4 million from $1,266.5 million, mostly due to $237.4 million in operational spending, including a $41.5 million fee to end a lease.

Furthermore, general and administration costs shot up to $165.4 million from $100.3 million due to commercial growth and lease expenses. Still, Arvinas beat analysts’ expectations in Q4, posting losses of $0.63 per share versus the predicted loss of $1.07 per share.

Looking ahead, Arvinas, Inc. (NASDAQ:ARVN) is pushing forward with ARV-102, a PROTAC targeting LRRK2 for neurodegenerative diseases. Early Phase 1 data showed favorable brain penetration, with further results expected at an upcoming medical conference. Moreover, the company is reinforcing its pipeline with plans to file paperwork for a new drug application for its KRAS G12D degrader with regulators in 2025.

With oncoming clinical results, key partnerships, and advances in protein degradation, Arvinas, Inc. (NASDAQ:ARVN) remains significant in the biotechnology industry, ranking among the stocks that will triple.